Federal grants to Axonis Therapeutics, Inc.
Axonis Therapeutics, Inc. in Boston, Massachusetts received $3.6 million in federal grants from fiscal 2021 to 2025, across 6 awards. Its largest program was Extramural Research Programs in the Neurosciences and Neurological Disorders, with $2.7 million. In fiscal 2025 more was taken back from its awards than added, a net -$206,417.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$3.6 million
- Awards6
- Awarded in FY 2025-$206,417
- Largest award$2.2 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 4 | $1.7 million |
| FY 2023 | 2 | $1.7 million |
| FY 2024 | 1 | $323,001 |
| FY 2025 | 0 | -$206,417 |
Programs that fund Axonis Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 3 | $2.7 million |
| Military Medical Research and Development | 1 | $316,091 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $299,756 |
| Vision Research | 1 | $298,819 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $3.3 million |
| Department of Defense | 1 | $316,091 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of KCC2 neuromodulators to treat paralysis after spinal cord injury. - development of KCC2 neuromodulators to treat spinal cord injury. Abstract: there are no approved therapies for treating paralysis after spinal cord injury (SCI), despite roughly 17,000 people suffering sci per year an | Extramural Research Programs in the Neurosciences and Neurological Disorders | February 25, 2022 | $2.2 million |
| Development of oral KCC2 potentiator AXN-027 as a novel anti-epileptic drug for mesial temporal lobe epilepsy - development of oral KCC2 potentiator AXN-027 as a novel anti-epileptic drug for mesial temporal lobe epilepsy abstract: patients with mesial temporal lobe epilepsy (MTLE) have spontaneous | Extramural Research Programs in the Neurosciences and Neurological Disorders | August 28, 2024 | $323,001 |
| Accelerating translation of a small-molecule KCC2 enhancer to promote recovery and reduce neuropathic pain after sci using a pig model | Military Medical Research and Development | September 16, 2022 | $316,091 |
| Development of oral KCC2 enhancer drug for treatment of painful diabetic neuropathy - development of oral KCC2 enhancer drug for treatment of painful diabetic neuropathy. Abstract: there is a need for more effective drug treatments for diabetic neuropathic pain (DNP), which affects one-third of peop | Diabetes, Digestive, and Kidney Diseases Extramural Research | June 15, 2023 | $299,756 |
| Development of AAV-AXN-007 gene therapy to treat glaucoma. - development of AAV-AXN-007 gene therapy to treat glaucoma abstract: glaucoma represents the world’s leading cause of irreversible blindness, with its prevalence increasing as the population ages. Vision loss in glaucoma is caused by a prog | Vision Research | August 17, 2022 | $298,819 |
| Development of neuromodulating AAV-KCC2 gene therapy to treat paralysis, spasticity and neuropathic pain after spinal cord injury. - summary there are no approved therapies for spinal cord injury. There are about 300,000 people living with chronic spinal cord injury in us. For the vast majority of t | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 23, 2022 | $129,251 |
Questions people ask
How much federal grant money does Axonis Therapeutics, Inc. get?
$3.6 million in 6 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Axonis Therapeutics, Inc. the most?
The Department of Health and Human Services, with $3.3 million in 5 awards. The Department of Defense follow.
What is Axonis Therapeutics, Inc.'s largest federal grant?
$2.2 million under Extramural Research Programs in the Neurosciences and Neurological Disorders, with its first action in the period on February 25, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Axonis Therapeutics, Inc.?
Its largest are Extramural Research Programs in the Neurosciences and Neurological Disorders, Military Medical Research and Development and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Boston
- The Commonwealth of Massachusetts
- Massachusetts Department of Transportation
- Massachusetts Bay Transportation Authority
- Department of Transitional Assistan
- The General Hospital Corporation
- Massachusetts Department of Public Health
- Brigham & Womens Hospital Inc
- Executive Office of Housing and Livable Communities
Largest federal grant recipients in Massachusetts · Federal grants in Massachusetts